Sign in with Google. Opens in new tab
bullish
Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading
547 Views27 Nov 2019 09:08
Pharmaron, the second-largest contract research organization (CRO), raised USD 560 m at HKD 39.50/share. In this insight, we will cover the...
SUMMARY
(Sign Up to Access)Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Curator's Cut: Building Materials Moves, Benchmarking Gold Miners & Semaglutide in India and Japan
- Korea Holdco Rerating Pullback Risk: No Retroactive Treasury Cancellation
- Nikkei 225 Index Rebalance: Rohm (6963) To Replace NTT Data Group (9613)
- [Quiddity Index] Nikkei 225 Sep25 Rebal: One ADD/DEL, Less Certain Than Before
- [Quiddity Index] Nikkei 225 Boots NTT Data (9613) Early, Rohm (6963) IN 3 July; $3.8bn a Side
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Price Chart(Sign Up to Access)
- Pharmaron Buy Support21 Sep 2020
- Long Pharmaron/Short Wuxi: Take Profit Now, A-Share Pullback the Key Risk23 Jan 2020
- Pharmaron (康龙化成) Post-IPO: A/H Convergence Post Connect Inclusion Supports A Trade02 Jan 2020
- Pharmaron (康龙化成) A+H: Allocation and Thoughts on Trading27 Nov 2019
- Pharmaron (康龙化成) A+H: Decent H/A Discount and Cornerstone Line-Up12 Nov 2019
- Pharmaron (康龙化成) A+H Listing: 3Q2019 Numbers and Thoughts on Valuation06 Nov 2019
x